MA38540A1 - Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 - Google Patents
Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6Info
- Publication number
- MA38540A1 MA38540A1 MA38540A MA38540A MA38540A1 MA 38540 A1 MA38540 A1 MA 38540A1 MA 38540 A MA38540 A MA 38540A MA 38540 A MA38540 A MA 38540A MA 38540 A1 MA38540 A1 MA 38540A1
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- alpha
- derivatives useful
- integrin antagonists
- naphthyridine derivatives
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 150000005054 naphthyridines Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention porte sur un composé de formule (i) ou un sel de celle-ci (i), dans laquelle r1 représente un atome d'hydrogène, un groupe méthyle ou un groupe éthyle, r2 représente un atome d'hydrogène ou un atome de fluor et r3 représente un atome d'hydrogène, un groupe méthyle ou un groupe éthyle.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1305668.4A GB201305668D0 (en) | 2013-03-28 | 2013-03-28 | Avs6 Integrin Antagonists |
| PCT/EP2014/056013 WO2014154725A1 (fr) | 2013-03-28 | 2014-03-26 | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38540A1 true MA38540A1 (fr) | 2017-02-28 |
| MA38540B1 MA38540B1 (fr) | 2017-10-31 |
Family
ID=48444909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38540A MA38540B1 (fr) | 2013-03-28 | 2014-03-26 | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US10023568B2 (fr) |
| EP (2) | EP2989100B1 (fr) |
| JP (1) | JP6095847B2 (fr) |
| KR (2) | KR101775085B1 (fr) |
| CN (1) | CN105189499B (fr) |
| AR (1) | AR095768A1 (fr) |
| AU (1) | AU2014243068C1 (fr) |
| BR (1) | BR112015024530A8 (fr) |
| CA (1) | CA2903358A1 (fr) |
| CL (1) | CL2015002860A1 (fr) |
| CR (1) | CR20150509A (fr) |
| CY (1) | CY1120188T1 (fr) |
| DK (1) | DK2989100T3 (fr) |
| DO (1) | DOP2015000251A (fr) |
| EA (1) | EA027305B1 (fr) |
| ES (1) | ES2665597T3 (fr) |
| GB (1) | GB201305668D0 (fr) |
| HR (1) | HRP20180528T1 (fr) |
| HU (1) | HUE036750T2 (fr) |
| IL (1) | IL241184A0 (fr) |
| LT (1) | LT2989100T (fr) |
| MA (1) | MA38540B1 (fr) |
| ME (1) | ME02987B (fr) |
| MX (1) | MX363288B (fr) |
| NO (1) | NO2989100T3 (fr) |
| NZ (1) | NZ629025A (fr) |
| PE (1) | PE20151606A1 (fr) |
| PH (1) | PH12015502232B1 (fr) |
| PL (1) | PL2989100T3 (fr) |
| PT (1) | PT2989100T (fr) |
| RS (1) | RS57220B1 (fr) |
| SG (1) | SG11201506813QA (fr) |
| SI (1) | SI2989100T1 (fr) |
| SM (1) | SMT201800247T1 (fr) |
| TW (1) | TWI632143B (fr) |
| UA (1) | UA114952C2 (fr) |
| UY (1) | UY35505A (fr) |
| WO (1) | WO2014154725A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3050878T1 (sl) | 2013-09-24 | 2022-01-31 | Fujifilm Corporation | Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te |
| GB201417094D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR20170123315A (ko) | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
| GB201615588D0 (en) | 2016-09-14 | 2016-10-26 | Glaxosmithkline Ip Dev Ltd | TSLP Binding Proteins |
| GB201604589D0 (en) * | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| BR112019009245A2 (pt) | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
| ES2984394T3 (es) | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| WO2018089357A1 (fr) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | DÉRIVÉS D'INDAZOLE EN TANT QU'ANTAGONISTES DE L'INTÉGRINE αV |
| HRP20210228T1 (hr) * | 2016-11-08 | 2021-03-19 | Bristol-Myers Squibb Company | Amidi pirola kao inhibitori alfa v integrina |
| AU2017359023B2 (en) | 2016-11-08 | 2021-12-09 | Bristol-Myers Squibb Company | 3-substituted propionic acids as alpha v integrin inhibitors |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| KR102700471B1 (ko) | 2017-11-07 | 2024-08-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 |
| FI3761980T3 (fi) | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| TWI841573B (zh) * | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020047208A1 (fr) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiteurs de l'intégrine (alpha-v)(bêta-6) |
| WO2020047239A1 (fr) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITION DE L'INTÉGRINE ανβ6 |
| WO2020047207A1 (fr) * | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibiteurs de l'intégrine (alpha-v)(bêta -6) |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| WO2022183360A1 (fr) * | 2021-03-02 | 2022-09-09 | Tsao Yeou Ping | Peptides synthétiques courts et leurs utilisations pour le traitement de la sécheresse oculaire |
| EP4605008A1 (fr) * | 2022-12-14 | 2025-08-27 | Alnylam Pharmaceuticals, Inc. | Ligands de l'intégrine alpha-v bêta-6 pour une distribution extra-hépatique |
| IL321740A (en) * | 2022-12-27 | 2025-08-01 | Pliant Therapeutics Inc | Alpha-V-beta-8 integrin inhibitors and their uses |
| WO2025259747A2 (fr) | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de protéine kinase myotonique de dystrophie (dmpk) et leurs procédés d'utilisation |
| WO2025259743A1 (fr) | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Composés conjugués doubles pour administration extrahépatique |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| KR20010033248A (ko) | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| CA2315370A1 (fr) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Antagonistes du recepteur de l'integrine |
| CN1589145A (zh) | 1999-06-02 | 2005-03-02 | 麦克公司 | αv整联蛋白受体拮抗剂 |
| WO2000078317A1 (fr) | 1999-06-23 | 2000-12-28 | Merck & Co., Inc. | Antagonistes des recepteurs de l'integrine |
| EP1229910A4 (fr) | 1999-10-04 | 2003-10-01 | Merck & Co Inc | Antagonistes des recepteurs d'integrine |
| PL355011A1 (en) * | 1999-11-08 | 2004-03-22 | Merck & Co, Inc. | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| US7119098B2 (en) | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
| AU7793501A (en) | 2000-07-26 | 2002-02-05 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| WO2002022616A2 (fr) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Antagonistes du recepteur des integrines alpha v |
| CA2432504A1 (fr) | 2001-01-03 | 2002-07-11 | Merck & Co., Inc. | Methodes et compositions de traitement d'une parodontopathie |
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| EP1592421A1 (fr) | 2002-12-20 | 2005-11-09 | Pharmacia Corporation | Acides heterocycliques comme antagonistes du recepteur d'integrin |
| US6932865B2 (en) | 2003-04-11 | 2005-08-23 | Lockheed Martin Corporation | System and method of making single-crystal structures through free-form fabrication techniques |
| CN1901958B (zh) | 2003-11-03 | 2011-03-09 | 葛兰素集团有限公司 | 流体分配装置 |
| EP2139882B1 (fr) | 2007-03-23 | 2013-12-25 | Amgen Inc. | Dérivés de quinoléine ou quinoxaline 3-substituée et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k) |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| EP2211615A4 (fr) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase |
| WO2011111880A1 (fr) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3 |
| WO2015048819A1 (fr) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Composés d'intégrine anti-aphavbêta1 et méthodes correspondantes |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| WO2016145258A1 (fr) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Inhibiteurs anti-intégrine alphavbeta1 et méthodes d'utilisation associées |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2013
- 2013-03-28 GB GBGB1305668.4A patent/GB201305668D0/en not_active Ceased
-
2014
- 2014-03-26 NO NO14712666A patent/NO2989100T3/no unknown
- 2014-03-26 PT PT147126668T patent/PT2989100T/pt unknown
- 2014-03-26 SI SI201430687T patent/SI2989100T1/en unknown
- 2014-03-26 RS RS20180537A patent/RS57220B1/sr unknown
- 2014-03-26 SM SM20180247T patent/SMT201800247T1/it unknown
- 2014-03-26 AU AU2014243068A patent/AU2014243068C1/en not_active Ceased
- 2014-03-26 US US14/778,095 patent/US10023568B2/en not_active Expired - Fee Related
- 2014-03-26 UA UAA201508518A patent/UA114952C2/uk unknown
- 2014-03-26 JP JP2016504647A patent/JP6095847B2/ja not_active Expired - Fee Related
- 2014-03-26 ES ES14712666.8T patent/ES2665597T3/es active Active
- 2014-03-26 KR KR1020157031064A patent/KR101775085B1/ko not_active Expired - Fee Related
- 2014-03-26 CN CN201480018839.6A patent/CN105189499B/zh not_active Expired - Fee Related
- 2014-03-26 PE PE2015002064A patent/PE20151606A1/es active IP Right Grant
- 2014-03-26 AR ARP140101378A patent/AR095768A1/es unknown
- 2014-03-26 MA MA38540A patent/MA38540B1/fr unknown
- 2014-03-26 KR KR1020177024389A patent/KR102042141B1/ko not_active Expired - Fee Related
- 2014-03-26 DK DK14712666.8T patent/DK2989100T3/en active
- 2014-03-26 NZ NZ629025A patent/NZ629025A/en not_active IP Right Cessation
- 2014-03-26 HR HRP20180528TT patent/HRP20180528T1/hr unknown
- 2014-03-26 ME MEP-2018-83A patent/ME02987B/fr unknown
- 2014-03-26 EP EP14712666.8A patent/EP2989100B1/fr active Active
- 2014-03-26 UY UY0001035505A patent/UY35505A/es not_active Application Discontinuation
- 2014-03-26 TW TW103111317A patent/TWI632143B/zh not_active IP Right Cessation
- 2014-03-26 WO PCT/EP2014/056013 patent/WO2014154725A1/fr not_active Ceased
- 2014-03-26 LT LTEP14712666.8T patent/LT2989100T/lt unknown
- 2014-03-26 CA CA2903358A patent/CA2903358A1/fr not_active Abandoned
- 2014-03-26 EP EP18157255.3A patent/EP3360876A1/fr not_active Withdrawn
- 2014-03-26 BR BR112015024530A patent/BR112015024530A8/pt not_active IP Right Cessation
- 2014-03-26 EA EA201591503A patent/EA027305B1/ru not_active IP Right Cessation
- 2014-03-26 SG SG11201506813QA patent/SG11201506813QA/en unknown
- 2014-03-26 PL PL14712666T patent/PL2989100T3/pl unknown
- 2014-03-26 HU HUE14712666A patent/HUE036750T2/hu unknown
- 2014-03-26 MX MX2015013742A patent/MX363288B/es unknown
-
2015
- 2015-09-06 IL IL241184A patent/IL241184A0/en active IP Right Grant
- 2015-09-24 PH PH12015502232A patent/PH12015502232B1/en unknown
- 2015-09-25 CL CL2015002860A patent/CL2015002860A1/es unknown
- 2015-09-28 CR CR20150509A patent/CR20150509A/es unknown
- 2015-09-28 DO DO2015000251A patent/DOP2015000251A/es unknown
-
2018
- 2018-05-09 CY CY20181100479T patent/CY1120188T1/el unknown
- 2018-06-13 US US16/007,584 patent/US10450312B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38540A1 (fr) | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| MA38390A1 (fr) | Composés tétrahydropyrrolothiazines | |
| MA38583B1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
| MA35172B1 (fr) | Melanges pestticides contenant des derives d'isoxazoline | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| MA34006B1 (fr) | Derives de dihydrofurane utilises comme composes insecticides | |
| MY156669A (en) | Pesticidal composition and its use | |
| MA38404A1 (fr) | Nouveaux dérivés de pyridine | |
| MA35663B1 (fr) | Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2 | |
| MX372721B (es) | Ánalogos halogenados de agentes antifi-broticos. | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| BR112018004447A2 (pt) | derivado de biarila e medicamento contendo o mesmo | |
| BR112012027378A2 (pt) | composto pesticida e seu uso | |
| PH12016500152A1 (en) | Novel triazine derivative | |
| BR112013015604A2 (pt) | novo derivado de isoquinolina substituído | |
| MA39305A3 (fr) | Dérivés d'éthynyle | |
| FR3020809B1 (fr) | Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique | |
| MA20150280A2 (fr) | Dérivés d'aryléthynyle | |
| MA38010B1 (fr) | Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5 | |
| IN2012DN01251A (fr) | ||
| BR112018000925A2 (pt) | composto heterocíclico contendo nitrogênio | |
| MX358151B (es) | Derivado de sitaxentan. | |
| BR112016029347A2 (pt) | ?repelente de animal roedor, e, método para repelir um animal roedor? |